Vor Biopharma Net Income From Continuing Ops Over Time
| VOR Stock | USD 12.79 0.21 1.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vor Biopharma Performance and Vor Biopharma Correlation. Can Biotechnology industry sustain growth momentum? Does Vor have expansion opportunities? Factors like these will boost the valuation of Vor Biopharma. If investors know Vor will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Vor Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Vor Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Vor Biopharma's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Vor Biopharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Vor Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vor Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Vor Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Vor Biopharma and related stocks such as Fate Therapeutics, Nkarta Inc, and Actuate Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FATE | (20.9 M) | (20.9 M) | (20.9 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (281.7 M) | (173.2 M) | (186.3 M) | (167.6 M) | (176 M) |
| NKTX | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (21.1 M) | (91.4 M) | (86.1 M) | (113.8 M) | (122.3 M) | (108.8 M) | (97.9 M) | (102.8 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.5 M) | (52.2 M) | (105.4 M) | (190.2 M) | (36.3 M) | (133.3 M) | (141.4 M) | (119 M) | (107.1 M) | (112.5 M) |
| FBRX | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (46.5 M) | (21.7 M) | (13.9 M) | (30.5 M) | (35.5 M) | (31.9 M) | (33.5 M) |
| PEPG | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (85 M) |
| ANIX | (7.4 M) | (4.3 M) | (10.1 M) | (9.6 M) | (1.4 M) | (5 M) | (5 M) | (14.2 M) | (11.8 M) | (9.9 M) | (13.1 M) | (13.8 M) | (9.9 M) | (12.7 M) | (11 M) | (9.9 M) | (10.4 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.5 M) | (94 M) | (105.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| MCRB | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (141.3 M) | (125.8 M) | (113.2 M) | (118.9 M) |
| SPRO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (32.6 M) | (39.9 M) | (41.7 M) | (60.9 M) | (78.3 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
Vor Biopharma and related stocks such as Fate Therapeutics, Nkarta Inc, and Actuate Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Vor Biopharma | VOR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 100 Cambridgepark Drive, |
| Exchange | NASDAQ Exchange |
USD 12.79
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.